Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411169 | 0.82 | PDE10A (0.43) | CRHR1KMT2AHTTMEN1HSD17B10 | |
| SCHEMBL15781884 | 0.82 | PDE10A (0.41) | CRHR1KMT2AHTTMEN1HSD17B10 | |
| SCHEMBL17131647 | 0.81 | IRAK4 (0.43) | CRHR1KMT2AHTTMEN1HSD17B10 | |
| SCHEMBL26239673 | 0.81 | GABRA1 (0.39) | CRHR1KMT2AHTTMEN1HSD17B10 | |
| SCHEMBL15781881 | 0.78 | PDE10A (0.44) | CRHR1KMT2AHTTMEN1HSD17B10 | |
| SCHEMBL12909531 | 0.77 | KMT2A (0.50) | CRHR1KMT2AHTTMEN1HSD17B10 | |
| SCHEMBL15635181 | 0.75 | DHODH (0.48) | HSD17B10PDE10AIRAK4KDM4EALDH1A1 | |
| SCHEMBL2813594 | 0.73 | MAPK1 (0.44) | KMT2AMEN1PDE10APOLBSMN1; SMN2 | |
| SCHEMBL7790446 | 0.73 | FDPS (0.55) | CRHR1 | |
| SCHEMBL1198968 | 0.72 | HTT (0.46) | CRHR1KMT2AHTTMEN1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-7879795-B2 | can be coadministered with antimicrobial agents for treatment of infections caused by drug resistant bacteria; 2-Amino-N-{4-Amino-1-[-3-phenyl-1-(R)-(quinolin-3-ylcarbomoyl)-propylcarbamoyl]-butyl}succinamic acid; 2,5-Diamino-pentanoic acid [3-phenyl-1-(R)-(4-phenyl-thiazol-2-ylcarbamoyl)-propyl]-amide | MPEX PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| WO-2009143156-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SEPRACOR INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | CRHR1 3513/4885KMT2A 3667/4885HTT 1693/4885 |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | CRHR1 3697/4885KMT2A 3952/4885HTT 1698/4885 |
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | CRHR1 4051/4885KMT2A 2401/4885HTT 2396/4885 |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB4 | CRHR1 3109/4885KMT2A 3588/4885HTT 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.